Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential immune responses to SFTSV Gn and Gc mRNA vaccines in mice and dogs.

Microbiology spectrum·2026
Same author

Correction: A targeted epigenetic clock for simultaneous assessment of biological aging and cancer-associated methylation drift.

Clinical epigenetics·2026
Same author

Co-occurrence patterns and source-oriented health risk assessment of heavy metal-organic combined pollution in soil: A case study of a typical area in the Lower Yangtze River Basin.

Journal of hazardous materials·2026
Same author

Spatiotemporal evolution and driving factors of water conservation capacity in Lanzhou City.

Scientific reports·2026
Same author

Analyzing the Prevalence and Associated Demographics of Syphilitic Retinitis and Syphilis in a Large U.S. Cohort.

Ocular immunology and inflammation·2026
Same author

5-Hydroxytryptamine Distribution Alteration in Both Neuron and Synapse of Tg(SOD1*G93A)1gur Mice: A Potential Intervention Candidate Strategy for Amyotrophic Lateral Sclerosis.

CNS neuroscience & therapeutics·2026

Related Experiment Video

Updated: Jul 5, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K

PD-1: A critical player and target for immune normalization.

Xuening Liu1, Alison Zhao2, Su Xiao1,3

  • 1Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.

Immunology
|January 25, 2024
PubMed
Summary

Immune system imbalances drive disease. Programmed cell death protein 1 (PD-1) blockade therapy shows promise but has side effects, shifting focus to immune normalization for safer treatments.

Keywords:
PD‐1PD‐1 blockadeimmune normalizationimmune therapy

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.2K
Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

11.2K

Related Experiment Videos

Last Updated: Jul 5, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.7K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.2K
Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

11.2K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Immune system imbalances are implicated in various diseases.
  • Immunotherapy, particularly targeting immune checkpoints like PD-1, offers therapeutic potential for tumors and immune-mediated diseases.
  • PD-1 inhibitors are established anti-cancer treatments, but adverse effects are increasingly recognized.

Purpose of the Study:

  • To review recent advancements in programmed cell death protein 1 (PD-1) research.
  • To explore the concept of immune normalization as a therapeutic goal.
  • To discuss the safety and targeted therapy aspects of PD-1 inhibitors.

Main Methods:

  • Literature review of recent studies on PD-1 pathway and immunotherapy.
  • Analysis of clinical data regarding PD-1 inhibitor efficacy and adverse events.
  • Synthesis of current understanding of immune normalization in disease treatment.

Main Results:

  • PD-1 blockade demonstrates significant efficacy in treating certain cancers and immune-related diseases.
  • Adverse side effects associated with PD-1 blockade necessitate careful management and exploration of safety profiles.
  • Emerging evidence supports immune normalization over immune enhancement as the optimal therapeutic strategy.

Conclusions:

  • Immune normalization represents a paradigm shift in treating diseases involving immune system dysregulation.
  • Further research into the safety and efficacy of PD-1 inhibitors is crucial for optimizing therapeutic outcomes.
  • Targeted therapies focusing on immune normalization hold promise for improved disease management and reduced toxicity.